An urgent need for innovation
Surgical standard of care for acute spinal cord injury patients has not substantially changed in three decades. Patients are treated with early decompressive surgery stabilizing the spine above and below the injury with metal implants, with subsequent spinal fusion across the stabilized segment.
Patients deserve better
Spinal cord injury has not been an area of significant investment by the biopharma community, and to date, there have been no technologies approved for the treatment of acute SCI.
At InVivo, we entered this field with a clear understanding of the challenges facing all who are living with the aftermath of spinal cord injury. Our efforts are fueled by deep insights into their needs and a commitment to improve their quality of life.
We’re here to redefine the treatment of spinal cord injury.
Spinal cord injury carries enormous personal and societal cost
Devastating spinal cord injuries can strike anyone of any background without warning. The most common causes of spinal cord injury are motor vehicle accidents and falls.
Patients’ lives may be forever altered by loss of motor, sensory and autonomic (bladder, bowel and sexual) function.